First-line pazopanib in metastatic renal cell carcinoma: Multicenter experience
Journal of B.U.ON., cilt.26, sa.6, ss.2571-2576, 2021 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 26 Sayı: 6
- Basım Tarihi: 2021
- Dergi Adı: Journal of B.U.ON.
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
- Sayfa Sayıları: ss.2571-2576
- Anahtar Kelimeler: MSKCC risk stratification, Pazopanib, Real life data, Renal cell carcinoma, Side effects
- Trakya Üniversitesi Adresli: Evet
Özet
Purpose: To investigate the efficacy and safety of pazopanib in the first line treatment of metastatic renal cell carcinoma in an everyday oncology practice population. Methods: Patients aged 18 years and older and histopathologically diagnosed with renal cell carcinoma between 2012 and 2020 were included in the study. All patients received pazopanib treatment at a daily dose of 800 mg. Radiological response was assessed every 12 weeks using abdominal and thoracic CT. The side effects were graded using National Cancer Institute Criteria (CTCAE v4.). Results: A total of 84 patients were included. The median age was 61 years (range: 37-87). There were 59 (70.2%) males and 25 (29.8%) females. The objective response rate (ORR: CR + PR) was 26.6%, while the disease control rate (DCR: CR + PR + SD) was 77.4% . Median progression-free survival (PFS) was 14.4 months (95%Cl, 8.0-20.7). The median overall survival (mOS) was 23.9 months (95%CI, 5.9-41.8). When compared, the MSKCC favorable group had a median OS of 37.8 vs. 22 and 6.5 months for the intermediate and poor risk groups, respectively (p=0.179). Multivariate analysis for OS revealed that more than 2 metastatic sites (p=0.025) and clear cell histology (p=0.015) were predictors of poor and improved survival, retrospectively. Conclusions: The results of this study revealed that patients with metastatic clear cell RCC outside the context of a randomized clinical study confirmed the efficacy and safety of pazopanib used as a first-line treatment in real-life conditions.